Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma

[1]  S. Kakizaki,et al.  A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy , 2021, Clinical Journal of Gastroenterology.

[2]  M. Imamura,et al.  Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab , 2021, Medicine.

[3]  Yulei N. Wang,et al.  Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance , 2021, Experimental Hematology & Oncology.

[4]  R. Lencioni,et al.  Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial , 2021, Cancer medicine.

[5]  K. Sugimachi,et al.  Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma , 2021, Clinical Journal of Gastroenterology.

[6]  J. Shindoh,et al.  Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma , 2021, Annals of Surgical Oncology.

[7]  Zhao-You Tang,et al.  Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations , 2021, Liver Cancer.

[8]  T. Oda,et al.  Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report , 2021, World journal of hepatology.

[9]  H. Yokoo,et al.  Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report , 2020, World journal of hepatology.

[10]  O. Nakahara,et al.  Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy , 2020, Surgical Case Reports.

[11]  T. Takayama,et al.  Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib , 2020, Medicine.

[12]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[13]  J. Furuse,et al.  Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma , 2020, Liver Cancer.

[14]  J. Shindoh,et al.  Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis , 2020, Liver Cancer.

[15]  T. Beppu,et al.  Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy , 2019, AntiCancer Research.

[16]  T. Murakami,et al.  Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  J. Shindoh,et al.  Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma , 2019, Journal of Gastrointestinal Surgery.

[18]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[19]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[20]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[21]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[22]  M. Makuuchi,et al.  The Feasibility of Third or More Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma. , 2015, Annals of surgery.

[23]  P. Böelle,et al.  Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. , 2015, Surgery.

[24]  J. Shindoh,et al.  Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy , 2013, Liver Cancer.

[25]  Yoshiyuki Suzuki,et al.  New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[26]  S. Kawasaki,et al.  The committee for revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma , 2010 .

[27]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[28]  Wei Yang,et al.  Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  S. Paggi,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[30]  Luigi Solbiati,et al.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? , 2007, Hepatology.

[31]  S. Todo,et al.  Living Donor Liver Transplantation for Adult Patients With Hepatocellular Carcinoma: Experience in Japan , 2004, Annals of surgery.

[32]  M. Makuuchi,et al.  Results of surgical and nonsurgical treatment for small‐sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan , 2000, Hepatology.

[33]  M. Makuuchi,et al.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure , 1998, Hepatology.

[34]  Patrick M M Bossuyt,et al.  Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. , 2012, The Lancet. Oncology.

[35]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[36]  Ryosuke Tateishi,et al.  nature publishing group ORIGINAL CONTRIBUTIONS 569 CME Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors LIVER , 2022 .